Evaluating insomnia in patients with metastatic lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prevalence of insomnia among patients diagnosed with metastatic non-small cell lung cancer. Participants will undergo a review of their medical charts and complete a questionnaire to provide insights into their sleep difficulties. The study focuses on patients receiving various lines of treatment or maintenance therapy, allowing for a comprehensive understanding of insomnia in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a diagnosis of metastatic non small cell lung cancer

  * Undergoing 1st, 2nd or 3rd line of treatment or are in maintenance therapy
  * Older than 18 years old at the time of diagnosis

Exclusion Criteria:

* Subjects will be excluded if they are considered to have advanced terminal cancer, severe depression or other psychiatric disorder or a sleep disorder other than insomnia (sleep apnea, restless leg syndrome, sleep related disorder of breathing), regular use of psychotropic medication other than hypnotics (eg antidepressants) per chart review

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Konstantinos Leventakos, M.D., Ph.D. — Mayo Clinic in Rochester

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• GT103 plus pembrolizumab for advanced STK11‑mutant non‑small cell lung cancer

  This trial tests whether adding GT103 to pembrolizumab can help adults with advanced or metastatic STK11‑mutant non‑small cell lung cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT07017829

• Combining sotorasib and trastuzumab deruxtecan for advanced KRAS G12C non-small cell lung cancer

  This trial tests whether giving sotorasib with trastuzumab deruxtecan is safe and can shrink tumors or slow progression in people with locally advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation and progressed after prior targeted therapy, immunotherapy, and chemotherapy.

  Recruiting at 9 sites Phase 1/2 National Cancer Institute (NCI) · Sacramento, California and 8 other locations · NCT07012031

• Photon VMAT craniospinal radiation for leptomeningeal disease from breast or non‑small cell lung cancer

  This trial tests whether craniospinal irradiation delivered with photon VMAT can help adults whose breast cancer or non‑small cell lung cancer has spread to the meninges (leptomeningeal disease).

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06910761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.